Ciancio G, Contreras N, Esquenazi V, Gomez C, Gharagozloo H, Burke G W, Garcia-Morales R, Olson L, Rosen A, Colona J, Roth D, Strauss J, Ricordi C, Miller J
Department of Surgery, University of Miami School of Medicine, Florida, USA.
Clin Transpl. 1999:159-72.
Of the 1,679 renal allografts performed at the University of Miami between January 1, 1979 and October 31, 1999, 1,154 were from cadaver donors (CAD), 515 were from living-related donors (LRD), and 10 were from living-unrelated donors. The 3 ethnic groups: Black Caribbean-African-American, Hispanic, and others were almost equally represented among recipients. Recipient ages ranged between 1-83 years. In the CAD group, HLA matching was emphasized so that no patient received a kidney with less than one DR match, and for the entire series a mean of 2.59 of 6 HLA antigens were matched between donors and recipients. Overall actuarial 20-year patient and graft survival rates were 65.3% and 30.7%, respectively, with 69.2% patient and 38.5% graft survival rates for LRD, and 65.6% patient and 29.0% graft survival rates for CAD recipients. Several factors adversely affected long-term graft outcome. African-Americans had an overall 20-year graft survival rate of 13.6% compared with 34% for non African-Americans (p < 0.001) (not dependent on patient survival). Diabetic patients had an overall 20-year graft survival rate of 13.5% versus 34.2% for non-diabetics (primarily dependent on patient survival). In the category of non African-American, non-diabetic patients under age 36 (n = 412), the 20-year patient survival rates in the LRD and CAD groups were 85.0% and 79.3%, respectively, and the graft survival rates were 55.7% and 46.5%, respectively. This differed markedly from the results for the entire series.
1979年1月1日至1999年10月31日期间，在迈阿密大学进行的1679例肾移植手术中，1154例来自尸体供者（CAD），515例来自亲属活体供者（LRD），10例来自非亲属活体供者。接受者中，加勒比黑人 - 非裔美国人、西班牙裔和其他三个种族群体的比例几乎相同。接受者年龄在1 - 83岁之间。在CAD组中，强调HLA配型，因此没有患者接受的肾脏DR配型少于一个，并且在整个系列中，供者和接受者之间平均6个HLA抗原中有2.59个相匹配。总体20年患者和移植物存活率分别为65.3%和30.7%，LRD组患者和移植物存活率分别为69.2%和38.5%，CAD接受者的患者和移植物存活率分别为65.6%和29.0%。几个因素对长期移植物结果产生不利影响。非裔美国人的总体20年移植物存活率为13.6%，而非非裔美国人的这一比例为34%（p < 0.001）（与患者存活率无关）。糖尿病患者的总体20年移植物存活率为13.5%，而非糖尿病患者为34.2%（主要取决于患者存活率）。在非非裔美国人、年龄小于36岁的非糖尿病患者类别（n = 412）中，LRD组和CAD组的20年患者存活率分别为85.0%和79.3%，移植物存活率分别为55.7%和46.5%。这与整个系列的结果明显不同。
